Glutamate-mediated excitotoxicity in schizophrenia: A review

European Neuropsychopharmacology

Volumn 24, Issue 10, 2014, Pages 1591-1605

  Plitman, Eric ^a,b   Nakajima, Shinichiro ^a,c   de la Fuente Sandoval, Camilo ^d   Gerretsen, Philip ^a,b   Chakravarty, M Mallar ^e,f   Kobylianskii, Jane ^g   Chung, Jun Ku ^a,b   Caravaggio, Fernando ^a,b   Iwata, Yusuke ^a,c   Remington, Gary ^a,b   Graff Guerrero, Ariel ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^e DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g QUEEN S UNIVERSITY   (Canada)

Author keywords

Excitotoxicity; Glutamate; Glutamine; MRS; Psychosis; Schizophrenia

Indexed keywords

GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

COMPUTER ASSISTED TOMOGRAPHY; EXCITOTOXICITY; HUMAN; NEUROANATOMY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PATHOPHYSIOLOGY; RECEPTOR DOWN REGULATION; REVIEW; SCHIZOPHRENIA; ANIMAL; BRAIN; METABOLISM; PATHOLOGY;

ANIMALS; BRAIN; GLUTAMIC ACID; HUMANS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84907983364     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.07.015     Document Type: Review

References (161)

1. Abbott C., Bustillo J. What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update. Curr. Opin. Psychiatry 2006, 19:135-139.
2. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., van Dyck C.H., Charney D.S., Innis R.B., Laruelle M. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry 1998, 155:761-767.
3. Adams B., Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J. Neurosci. 1998, 18:5545-5554.
4. Adams B.W., Moghaddam B. Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol. Psychiatry 2001, 50:750-757.
5. Adler C.M., Malhotra A.K., Elman I., Goldberg T., Egan M., Pickar D., Breier A. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am. J. Psychiatry 1999, 156:1646-1649.
6. Anand A., Charney D.S., Oren D.A., Berman R.M., Hu X.S., Cappiello A., Krystal J.H. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-d-aspartate receptor antagonists. Arch. Gen. Psychiatry 2000, 57:270-276.
7. Anticevic A., Gancsos M., Murray J.D., Repovs G., Driesen N.R., Ennis D.J., Niciu M.J., Morgan P.T., Surti T.S., Bloch M.H., Ramani R., Smith M.A., Wang X.J., Krystal J.H., Corlett P.R. NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. Proc. Natl. Acad. Sci. USA 2012, 109:16720-16725.
8. Aoyama N., Theberge J., Drost D.J., Manchanda R., Northcott S., Neufeld R.W., Menon R.S., Rajakumar N., Pavlosky W.F., Densmore M., Schaefer B., Williamson P.C. Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. Br. J. Psychiatry 2011, 198:448-456.
9. Arango C., Rapado-Castro M., Reig S., Castro-Fornieles J., Gonzalez-Pinto A., Otero S., Baeza I., Moreno C., Graell M., Janssen J., Parellada M., Moreno D., Bargallo N., Desco M. Progressive brain changes in children and adolescents with first-episode psychosis. Arch. Gen. Psychiatry 2012, 69:16-26.
10. Auer R.N. Effect of age and sex on N-methyl-d-aspartate antagonist-induced neuronal necrosis in rats. Stroke 1996, 27:743-746.
11. Bartha R., al-Semaan Y.M., Williamson P.C., Drost D.J., Malla A.K., Carr T.J., Densmore M., Canaran G., Neufeld R.W. A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients. Biol. Psychiatry 1999, 45:1403-1411.
12. Bartha R., Williamson P.C., Drost D.J., Malla A., Carr T.J., Cortese L., Canaran G., Rylett R.J., Neufeld R.W. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 1997, 54:959-965.
13. Belousov A.B. Novel model for the mechanisms of glutamate-dependent excitotoxicity: role of neuronal gap junctions. Brain Res. 2012, 1487:123-130.
14. Bora E., Fornito A., Radua J., Walterfang M., Seal M., Wood S.J., Yucel M., Velakoulis D., Pantelis C. Neuroanatomical abnormalities in schizophrenia: a multimodal voxelwise meta-analysis and meta-regression analysis. Schizophr. Res. 2011, 127:46-57.
15. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. USA 1997, 94:2569-2574.
16. Brugger S., Davis J.M., Leucht S., Stone J.M. Proton magnetic resonance spectroscopy and illness stage in schizophrenia-a systematic review and meta-analysis. Biol. Psychiatry 2011, 69:495-503.
17. Bustillo J., Galloway M.P., Ghoddoussi F., Bolognani F., Perrone-Bizzozero N. Medial-frontal cortex hypometabolism in chronic phencyclidine exposed rats assessed by high resolution magic angle spin 11.7T proton magnetic resonance spectroscopy. Neurochem. Int. 2012, 61:128-131.
18. Bustillo J.R., Chen H., Gasparovic C., Mullins P., Caprihan A., Qualls C., Apfeldorf W., Lauriello J., Posse S. Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4T. Biol. Psychiatry 2011, 69:19-27.
19. Bustos G., Abarca J., Forray M.I., Gysling K., Bradberry C.W., Roth R.H. Regulation of excitatory amino acid release by N-methyl-d-aspartate receptors in rat striatum: in vivo microdialysis studies. Brain Res. 1992, 585:105-115.
20. Carter K., Dickerson J., Schoepp D.D., Reilly M., Herring N., Williams J., Sallee F.R., Sharp J.W., Sharp F.R. The mGlu2/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: possible implications for psychosis. Neuropharmacology 2004, 47:1135-1145.
21. Chan R.C., Di X., McAlonan G.M., Gong Q.Y. Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: an activation likelihood estimation meta-analysis of illness progression. Schizophr. Bull. 2011, 37:177-188.
22. Chen Z., Deng W., Gong Q., Huang C., Jiang L., Li M., He Z., Wang Q., Ma X., Wang Y., Chua S.E., McAlonan G.M., Sham P.C., Collier D.A., McGuire P., Li T. Extensive brain structural network abnormality in first-episode treatment-naive patients with schizophrenia: morphometrical and covariation study. Psychol. Med. 2014, 44:2489-2501.
23. Choi D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988, 1:623-634.
24. Colibazzi T., Wexler B.E., Bansal R., Hao X., Liu J., Sanchez-Pena J., Corcoran C., Lieberman J.A., Peterson B.S. Anatomical abnormalities in gray and white matter of the cortical surface in persons with schizophrenia. PloS One 2013, 8:e55783.
25. Connor C.M., Crawford B.C., Akbarian S. White matter neuron alterations in schizophrenia and related disorders. Int. J. Dev. Neurosci. 2011, 29:325-334.
26. Coyle J.T., Tsai G., Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann. N. Y. Acad. Sci. 2003, 1003:318-327.
27. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192:481-483. (New York, N.Y.).
28. Deakin J.F., Lees J., McKie S., Hallak J.E., Williams S.R., Dursun S.M. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch. Gen. Psychiatry 2008, 65:154-164.
29. Demjaha A., Egerton A., Murray R.M., Kapur S., Howes O.D., Stone J.M., McGuire P.K. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol. Psychiatry 2014, 75:e11-e13.
30. Deutsch S.I., Rosse R.B., Schwartz B.L., Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin. Neuropharmacol. 2001, 24:43-49.
31. de la Fuente-Sandoval C., Leon-Ortiz P., Azcarraga M., Favila R., Stephano S., Graff-Guerrero A. Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study. Int. J. Neuropsychopharmacol. 2013, 16:471-475.
32. de la Fuente-Sandoval C., Leon-Ortiz P., Azcarraga M., Stephano S., Favila R., Diaz-Galvis L., Alvarado-Alanis P., Ramirez-Bermudez J., Graff-Guerrero A. Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry 2013, 70:1057-1066.
33. de la Fuente-Sandoval C., Leon-Ortiz P., Favila R., Stephano S., Mamo D., Ramirez-Bermudez J., Graff-Guerrero A. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 2011, 36:1781-1791.
34. Doyle O.M., De Simoni S., Schwarz A.J., Brittain C., O'Daly O.G., Williams S.C., Mehta M.A. Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: a validation using antipsychotic and glutamatergic agents. J. Pharmacol. Exp. Ther. 2013, 345:151-160.
35. Duncan N.W., Wiebking C., Tiret B., Marjanska M., Hayes D.J., Lyttleton O., Doyon J., Northoff G. Glutamate concentration in the medial prefrontal cortex predicts resting-state cortical-subcortical functional connectivity in humans. PloS One 2013, 8:e60312.
36. Egerton A., Brugger S., Raffin M., Barker G.J., Lythgoe D.J., McGuire P.K., Stone J.M. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology 2012, 37:2515-2521.
37. Ellison G. Competitive and non-competitive NMDA antagonists induce similar limbic degeneration. Neuroreport 1994, 5:2688-2692.
38. Ellison-Wright I., Glahn D.C., Laird A.R., Thelen S.M., Bullmore E. The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. Am. J. Psychiatry 2008, 165:1015-1023.
39. Eyjolfsson E.M., Nilsen L.H., Kondziella D., Brenner E., Haberg A., Sonnewald U. Altered 13C glucose metabolism in the cortico-striato-thalamo-cortical loop in the MK-801 rat model of schizophrenia. J. Cereb. Blood Flow Metab. 2011, 31:976-985.
40. Farber N.B. The NMDA receptor hypofunction model of psychosis. Ann. N. Y. Acad. Sci. 2003, 1003:119-130.
41. Farber N.B., Kim S.H., Dikranian K., Jiang X.P., Heinkel C. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol. Psychiatry 2002, 7:32-43.
42. Farber N.B., Wozniak D.F., Price M.T., Labruyere J., Huss J., Peter H., Olney J.W. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?. Biol. Psychiatry 1995, 38:788-796.
43. Fornito A., Yucel M., Wood S.J., Adamson C., Velakoulis D., Saling M.M., McGorry P.D., Pantelis C. Surface-based morphometry of the anterior cingulate cortex in first episode schizophrenia. Hum. Brain Mapp. 2008, 29:478-489.
44. Frangou S. Schizophrenia. Medicine 2008, 36:405-409.
45. George M., Amrutheshwar R., Rajkumar R.P., Kattimani S., Dkhar S.A. Newer antipsychotics and upcoming molecules for schizophrenia. Eur. J. Clin. Pharmacol. 2013, 69:1497-1509.
46. Glahn D.C., Laird A.R., Ellison-Wright I., Thelen S.M., Robinson J.L., Lancaster J.L., Bullmore E., Fox P.T. Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis. Biol. Psychiatry 2008, 64:774-781.
47. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 2001, 158:1367-1377.
48. Goldman A.L., Pezawas L., Mattay V.S., Fischl B., Verchinski B.A., Chen Q., Weinberger D.R., Meyer-Lindenberg A. Widespread reductions of cortical thickness in schizophrenia and spectrum disorders and evidence of heritability. Arch. Gen. Psychiatry 2009, 66:467-477.
49. Goto N., Yoshimura R., Kakeda S., Nishimura J., Moriya J., Hayashi K., Katsuki A., Hori H., Umene-Nakano W., Ikenouchi-Sugita A., Korogi Y., Nakamura J. Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia. Neuropsychiatr. Dis. Treat. 2012, 8:119-122.
50. Gruber O., Hasan A., Scherk H., Wobrock T., Schneider-Axmann T., Ekawardhani S., Schmitt A., Backens M., Reith W., Meyer J., Falkai P. Association of the brain-derived neurotrophic factor val66met polymorphism with magnetic resonance spectroscopic markers in the human hippocampus: in vivo evidence for effects on the glutamate system. Eur. Arch. Psychiatry Clin. Neurosci. 2012, 262:23-31.
51. Hardingham G.E., Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat. Rev. Neurosci. 2010, 11:682-696.
52. Hargreaves R.J., Rigby M., Smith D., Hill R.G., Iversen L.L. Competitive as well as uncompetitive N-methyl-d-aspartate receptor antagonists affect cortical neuronal morphology and cerebral glucose metabolism. Neurochem. Res. 1993, 18:1263-1269.
53. Heresco-Levy U. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia. Expert Opin. Emerg. Drugs 2005, 10:827-844.
54. Hietala J., Syvalahti E., Vuorio K., Rakkolainen V., Bergman J., Haaparanta M., Solin O., Kuoppamaki M., Kirvela O., Ruotsalainen U., et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995, 346:1130-1131.
55. Honea R., Crow T.J., Passingham D., Mackay C.E. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am. J. Psychiatry 2005, 162:2233-2245.
56. Hulshoff Pol H.E., Kahn R.S. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr. Bull. 2008, 34:354-366.
57. Hutcheson N.L., Reid M.A., White D.M., Kraguljac N.V., Avsar K.B., Bolding M.S., Knowlton R.C., den Hollander J.A., Lahti A.C. Multimodal analysis of the hippocampus in schizophrenia using proton magnetic resonance spectroscopy and functional magnetic resonance imaging. Schizophr. Res. 2012, 140:136-142.
58. Ikonomidou C., Bosch F., Miksa M., Bittigau P., Vockler J., Dikranian K., Tenkova T.I., Stefovska V., Turski L., Olney J.W. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 1999, 283:70-74. (New York, N.Y.).
59. Iltis I., Koski D.M., Eberly L.E., Nelson C.D., Deelchand D.K., Valette J., Ugurbil K., Lim K.O., Henry P.G. Neurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: an in vivo localized (1)H MRS study. NMR Biomed. 2009, 22:737-744.
60. Javitt D.C. Glutamate and schizophrenia: phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int. Rev. Neurobiol. 2007, 78:69-108.
61. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148:1301-1308.
62. Javitt D.C., Zukin S.R., Heresco-Levy U., Umbricht D. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr. Bull. 2012, 38:958-966.
63. Kantrowitz J., Javitt D.C. Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Curr. Opin. Psychiatry 2012, 25:96-102.
64. Kegeles L.S., Mao X., Stanford A.D., Girgis R., Ojeil N., Xu X., Gil R., Slifstein M., Abi-Dargham A., Lisanby S.H., Shungu D.C. Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 2012, 69:449-459.
65. Kegeles L.S., Shungu D.C., Anjilvel S., Chan S., Ellis S.P., Xanthopoulos E., Malaspina D., Gorman J.M., Mann J.J., Laruelle M., Kaufmann C.A. Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies. Psychiatry Res. 2000, 98:163-175.
66. Kessler R.C., Amminger G.P., Aguilar-Gaxiola S., Alonso J., Lee S., Ustun T.B. Age of onset of mental disorders: a review of recent literature. Curr. Opin. Psychiatry 2007, 20:359-364.
67. Klar A.A., Ballmaier M., Leopold K., Hake I., Schaefer M., Bruhl R., Schubert F., Gallinat J. Interaction of hippocampal volume and N-acetylaspartate concentration deficits in schizophrenia: a combined MRI and 1H-MRS study. NeuroImage 2010, 53:51-57.
68. Kondziella D., Brenner E., Eyjolfsson E.M., Markinhuhta K.R., Carlsson M.L., Sonnewald U. Glial-neuronal interactions are impaired in the schizophrenia model of repeated MK801 exposure. Neuropsychopharmacology 2006, 31:1880-1887.
69. Kraguljac N.V., Reid M.A., White D.M., den Hollander J., Lahti A.C. Regional decoupling of N-acetyl-aspartate and glutamate in schizophrenia. Neuropsychopharmacology 2012, 37:2635-2642.
70. Kraguljac N.V., White D.M., Reid M.A., Lahti A.C. Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry 2013, 70:1294-1302.
71. Krystal J.H., Bennett A., Abi-Saab D., Belger A., Karper L.P., D'Souza D.C., Lipschitz D., Abi-Dargham A., Charney D.S. Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biol. Psychiatry 2000, 47:137-143.
72. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
73. Krystal J.H., Perry E.B., Gueorguieva R., Belger A., Madonick S.H., Abi-Dargham A., Cooper T.B., Macdougall L., Abi-Saab W., D'Souza D.C. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch. Gen. Psychiatry 2005, 62:985-994.
74. Kuperberg G.R., Broome M.R., McGuire P.K., David A.S., Eddy M., Ozawa F., Goff D., West W.C., Williams S.C., van der Kouwe A.J., Salat D.H., Dale A.M., Fischl B. Regionally localized thinning of the cerebral cortex in schizophrenia. Arch. Gen. Psychiatry 2003, 60:878-888.
75. Lahti A.C., Holcomb H.H., Medoff D.R., Tamminga C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995, 6:869-872.
76. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995, 13:9-19.
77. Lahti A.C., Reid M.A. Is there evidence for neurotoxicity in the prodromal and early stages of schizophrenia?. Neuropsychopharmacology 2011, 36:1779-1780.
78. Large C.H., Webster E.L., Goff D.C. The potential role of lamotrigine in schizophrenia. Psychopharmacology 2005, 181:415-436.
79. Laruelle M., Abi-Dargham A., Van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Fingado C., Baldwin R.M., Krystal J.H., Charney D.S., Innis R.B., Seibyl J.P., Rosenblatt W., Zoghbi S.S. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. USA 1996, 93:9235.
80. Lau A., Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch. 2010, 460:525-542.
81. Lawrie S.M., Abukmeil S.S. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. Br. J. Psychiatry 1998, 172:110-120.
82. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K., Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry 2001, 50:884-897.
83. Lindenmayer J.P. Treatment refractory schizophrenia. Psychiatr. Q. 2000, 71:373-384.
84. Lorrain D.S., Baccei C.S., Bristow L.J., Anderson J.J., Varney M.A. Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003, 117:697-706.
85. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996, 14:301-307.
86. Marsman A., van den Heuvel M.P., Klomp D.W., Kahn R.S., Luijten P.R., Hulshoff Pol H.E. Glutamate in schizophrenia: a focused review and meta-analysis of (1)H-MRS studies. Schizophr. Bull. 2013, 39:120-129.
87. McGorry P.D., Nelson B., Amminger G.P., Bechdolf A., Francey S.M., Berger G., Riecher-Rossler A., Klosterkotter J., Ruhrmann S., Schultze-Lutter F., Nordentoft M., Hickie I., McGuire P., Berk M., Chen E.Y., Keshavan M.S., Yung A.R. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J. Clin. Psychiatry 2009, 70:1206-1212.
88. Mehta A., Prabhakar M., Kumar P., Deshmukh R., Sharma P.L. Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur. J. Pharmacol. 2013, 698:6-18.
89. Meyer-Lindenberg A. Neuroimaging and the question of neurodegeneration in schizophrenia. Prog. Neurobiol. 2011, 95:514-516.
90. Miyamoto S., Miyake N., Jarskog L.F., Fleischhacker W.W., Lieberman J.A. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol. Psychiatry 2012, 17:1206-1227.
91. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 1997, 17:2921-2927.
92. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281:1349-1352. (New York, N.Y.).
93. Moghaddam B., Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012, 37:4-15.
94. Moghaddam B., Krystal J.H. Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr. Bull. 2012, 38:942-949.
95. Moncrieff J., Leo J. A systematic review of the effects of antipsychotic drugs on brain volume. Psychol. Med. 2010, 40:1409-1422.
96. Nagels A., Kirner-Veselinovic A., Krach S., Kircher T. Neural correlates of S-ketamine induced psychosis during overt continuous verbal fluency. NeuroImage 2011, 54:1307-1314.
97. Nakazawa K., Zsiros V., Jiang Z., Nakao K., Kolata S., Zhang S., Belforte J.E. GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 2012, 62:1574-1583.
98. Narr K.L., Toga A.W., Szeszko P., Thompson P.M., Woods R.P., Robinson D., Sevy S., Wang Y., Schrock K., Bilder R.M. Cortical thinning in cingulate and occipital cortices in first episode schizophrenia. Biol. Psychiatry 2005, 58:32-40.
99. Natsubori T., Inoue H., Abe O., Takano Y., Iwashiro N., Aoki Y., Koike S., Yahata N., Katsura M., Gonoi W., Sasaki H., Takao H., Kasai K., Yamasue H. Reduced Frontal glutamate+glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia. Schizophr. Bull 2013, 10.1093/schbul/sbt124.
100. Navari S., Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol. Med. 2009, 39:1763-1777.
101. Nazeri A., Chakravarty M.M., Felsky D., Lobaugh N.J., Rajji T.K., Mulsant B.H., Voineskos A.N. Alterations of superficial white matter in schizophrenia and relationship to cognitive performance. Neuropsychopharmacology 2013, 38:1954-1962.
102. Nelson B., Yuen H.P., Wood S.J., Lin A., Spiliotacopoulos D., Bruxner A., Broussard C., Simmons M., Foley D.L., Brewer W.J., Francey S.M., Amminger G.P., Thompson A., McGorry P.D., Yung A.R. Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis: the PACE 400 study. JAMA Psychiatry 2013, 70:793-802.
103. Ohrmann P., Siegmund A., Suslow T., Spitzberg K., Kersting A., Arolt V., Heindel W., Pfleiderer B. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr. Res. 2005, 73:153-157.
104. Okamura N., Hashimoto K., Shimizu E., Koike K., Ohgake S., Koizumi H., Kumakiri C., Komatsu N., Iyo M. Protective effect of LY379268, a selective group II metabotropic glutamate receptor agonist, on dizocilpine-induced neuropathological changes in rat retrosplenial cortex. Brain Res. 2003, 992:114-119.
105. Olney J.W. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 1969, 164:719-721. (New York, N.Y.).
106. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 1995, 52:998-1007.
107. Olney J.W., Labruyere J., Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989, 244:1360-1362. (New York, N.Y.).
108. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 1999, 33:523-533.
109. Olney J.W., Sharpe L.G. Brain lesions in an infant rhesus monkey treated with monsodium glutamate. Science 1969, 166:386-388. (New York, N.Y.).
110. Pilowsky L.S., Bressan R.A., Stone J.M., Erlandsson K., Mulligan R.S., Krystal J.H., Ell P.J. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol. Psychiatry 2006, 11:118-119.
111. Poels E.M., Kegeles L.S., Kantrowitz J.T., Javitt D.C., Lieberman J.A., Abi-Dargham A., Girgis R.R. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr. Res. 2014, 152:325-332.
112. Poels E.M., Kegeles L.S., Kantrowitz J.T., Slifstein M., Javitt D.C., Lieberman J.A., Abi-Dargham A., Girgis R.R. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol. Psychiatry 2014, 19:20-29.
113. Purdon S.E., Valiakalayil A., Hanstock C.C., Seres P., Tibbo P. Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-0X) scores and genetic risk for schizophrenia. Schizophr. Res. 2008, 99:218-224.
114. Rais M., van Haren N.E., Cahn W., Schnack H.G., Lepage C., Collins L., Evans A.C., Hulshoff Pol H.E., Kahn R.S. Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia. Eur. Neuropsychopharmacol. 2010, 20:855-865.
115. Reich D.L., Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can. J. Anaesth. 1989, 36:186-197.
116. Reid M.A., Stoeckel L.E., White D.M., Avsar K.B., Bolding M.S., Akella N.S., Knowlton R.C., den Hollander J.A., Lahti A.C. Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol. Psychiatry 2010, 68:625-633.
117. Ren W., Lui S., Deng W., Li F., Li M., Huang X., Wang Y., Li T., Sweeney J.A., Gong Q. Anatomical and functional brain abnormalities in drug-naive first-episode schizophrenia. Am. J. Psychiatry 2013, 170:1308-1316.
118. Reynolds L.M., Cochran S.M., Morris B.J., Pratt J.A., Reynolds G.P. Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain. Schizophr. Res. 2005, 73:147-152.
119. Rimol L.M., Hartberg C.B., Nesvag R., Fennema-Notestine C., Hagler D.J., Pung C.J., Jennings R.G., Haukvik U.K., Lange E., Nakstad P.H., Melle I., Andreassen O.A., Dale A.M., Agartz I. Cortical thickness and subcortical volumes in schizophrenia and bipolar disorder. Biol. Psychiatry 2010, 68:41-50.
120. Rothman D.L., De Feyter H.M., de Graaf R.A., Mason G.F., Behar K.L. 13C MRS studies of neuroenergetics and neurotransmitter cycling in humans. NMR Biomed. 2011, 24:943-957.
121. Rowland L.M., Bustillo J.R., Mullins P.G., Jung R.E., Lenroot R., Landgraf E., Barrow R., Yeo R., Lauriello J., Brooks W.M. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am. J. Psychiatry 2005, 162:394-396.
122. Rowland L.M., Kontson K., West J., Edden R.A., Zhu H., Wijtenburg S.A., Holcomb H.H., Barker P.B. In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr. Bull. 2013, 39:1096-1104.
123. Rusch N., Tebartz van Elst L., Valerius G., Buchert M., Thiel T., Ebert D., Hennig J., Olbrich H.M. Neurochemical and structural correlates of executive dysfunction in schizophrenia. Schizophr. Res. 2008, 99:155-163.
124. Schobel S.A., Chaudhury N.H., Khan U.A., Paniagua B., Styner M.A., Asllani I., Inbar B.P., Corcoran C.M., Lieberman J.A., Moore H., Small S.A. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron 2013, 78:81-93.
125. Schultz C.C., Koch K., Wagner G., Roebel M., Schachtzabel C., Gaser C., Nenadic I., Reichenbach J.R., Sauer H., Schlosser R.G. Reduced cortical thickness in first episode schizophrenia. Schizophr. Res. 2010, 116:204-209.
126. Seeman P., Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975, 188:1217-1219. (New York, N.Y.).
127. Sharp F.R., Butman M., Koistinaho J., Aardalen K., Nakki R., Massa S.M., Swanson R.A., Sagar S.M. Phencyclidine induction of the hsp 70 stress gene in injured pyramidal neurons is mediated via multiple receptors and voltage gated calcium channels. Neuroscience 1994, 62:1079-1092.
128. Sharp F.R., Jasper P., Hall J., Noble L., Sagar S.M. MK-801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex. Ann. Neurol. 1991, 30:801-809.
129. Sharp F.R., Tomitaka M., Bernaudin M., Tomitaka S. Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia?. Trends Neurosci. 2001, 24:330-334.
130. Sharp J.W., Petersen D.L., Langford M.T. DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp70 heat shock gene in the rat cingulate and retrosplenial cortex. Brain Res. 1995, 687:114-124.
131. Shenton M.E., Dickey C.C., Frumin M., McCarley R.W. A review of MRI findings in schizophrenia. Schizophr. Res. 2001, 49:1-52.
132. Sprooten E., Papmeyer M., Smyth A.M., Vincenz D., Honold S., Conlon G.A., Moorhead T.W., Job D., Whalley H.C., Hall J., McIntosh A.M., Owens D.C., Johnstone E.C., Lawrie S.M. Cortical thickness in first-episode schizophrenia patients and individuals at high familial risk: a cross-sectional comparison. Schizophr. Res. 2013, 151:259-264.
133. Steen R.G., Hamer R.M., Lieberman J.A. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 2005, 30:1949-1962.
134. Steen R.G., Mull C., McClure R., Hamer R.M., Lieberman J.A. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br. J. Psychiatry 2006, 188:510-518.
135. Stone J.M., Day F., Tsagaraki H., Valli I., McLean M.A., Lythgoe D.J., O'Gorman R.L., Barker G.J., McGuire P.K. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol. Psychiatry 2009, 66:533-539.
136. Stone J.M., Dietrich C., Edden R., Mehta M.A., De Simoni S., Reed L.J., Krystal J.H., Nutt D., Barker G.J. Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol. Psychiatry 2012, 17:664-665.
137. Stone J.M., Erlandsson K., Arstad E., Bressan R.A., Squassante L., Teneggi V., Ell P.J., Pilowsky L.S. Ketamine displaces the novel NMDA receptor SPET probe [(123)I]CNS-1261 in humans in vivo. Nucl. Med. Biol. 2006, 33:239-243.
138. Stone J.M., Morrison P.D., Pilowsky L.S. Glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review. J. Psychopharmacol. 2007, 21:440-452.
139. Sullivan P.F., Kendler K.S., Neale M.C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch. Gen. Psychiatry 2003, 60:1187-1192.
140. Suzuki T., Remington G., Mulsant B.H., Rajji T.K., Uchida H., Graff-Guerrero A., Mamo D.C. Treatment resistant schizophrenia and response to antipsychotics: a review. Schizophr. Res. 2011, 133:54-62.
141. Tandon N., Bolo N.R., Sanghavi K., Mathew I.T., Francis A.N., Stanley J.A., Keshavan M.S. Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy. Schizophr. Res. 2013, 148:59-66.
142. Theberge J., Al-Semaan Y., Williamson P.C., Menon R.S., Neufeld R.W., Rajakumar N., Schaefer B., Densmore M., Drost D.J. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am. J. Psychiatry 2003, 160:2231-2233.
143. Theberge J., Bartha R., Drost D.J., Menon R.S., Malla A., Takhar J., Neufeld R.W., Rogers J., Pavlosky W., Schaefer B., Densmore M., Al-Semaan Y., Williamson P.C. Glutamate and glutamine measured with 4.0T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am. J. Psychiatry 2002, 159:1944-1946.
144. Theberge J., Williamson K.E., Aoyama N., Drost D.J., Manchanda R., Malla A.K., Northcott S., Menon R.S., Neufeld R.W., Rajakumar N., Pavlosky W., Densmore M., Schaefer B., Williamson P.C. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br. J. Psychiatry 2007, 191:325-334.
145. Tomitaka S., Tomitaka M., Tolliver B.K., Sharp F.R. Bilateral blockade of NMDA receptors in anterior thalamus by dizocilpine (MK-801) injures pyramidal neurons in rat retrosplenial cortex. Eur. J. Neurosci. 2000, 12:1420-1430.
146. Torres U.S., Portela-Oliveira E., Borgwardt S., Busatto G.F. Structural brain changes associated with antipsychotic treatment in schizophrenia as revealed by voxel-based morphometric MRI: an activation likelihood estimation meta-analysis. BMC Psychiatry 2013, 13:342.
147. Tsai G., Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. Toxicol. 2002, 42:165-179.
148. Tsai G., van Kammen D.P., Chen S., Kelley M.E., Grier A., Coyle J.T. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol. Psychiatry 1998, 44:667-674.
149. Valli I., Stone J., Mechelli A., Bhattacharyya S., Raffin M., Allen P., Fusar-Poli P., Lythgoe D., O'Gorman R., Seal M., McGuire P. Altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosis. Biol. Psychiatry 2011, 69:97-99.
150. Venkatasubramanian G., Jayakumar P.N., Gangadhar B.N., Keshavan M.S. Automated MRI parcellation study of regional volume and thickness of prefrontal cortex (PFC) in antipsychotic-naive schizophrenia. Acta Psychiatr. Scand. 2008, 117:420-431.
151. Vita A., De Peri L., Deste G., Sacchetti E. Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. Transl. Psychiatry 2012, 2:e190.
152. Voineskos A.N., Foussias G., Lerch J., Felsky D., Remington G., Rajji T.K., Lobaugh N., Pollock B.G., Mulsant B.H. Neuroimaging evidence for the deficit subtype of schizophrenia. JAMA Psychiatry 2013, 70:472-480.
153. Vollenweider F.X., Geyer M.A. A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res. Bull. 2001, 56:495-507.
154. Weiser M., Davidson M., Noy S. Comments on risk for schizophrenia. Schizophr. Res. 2005, 79:15-21.
155. Weiser M., Heresco-Levy U., Davidson M., Javitt D.C., Werbeloff N., Gershon A.A., Abramovich Y., Amital D., Doron A., Konas S., Levkovitz Y., Liba D., Teitelbaum A., Mashiach M., Zimmerman Y. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J. Clin. Psychiatry 2012, 73:e728-e734.
156. White T., Andreasen N.C., Nopoulos P., Magnotta V. Gyrification abnormalities in childhood- and adolescent-onset schizophrenia. Biol. Psychiatry 2003, 54:418-426.
157. Wood S.J., Kennedy D., Phillips L.J., Seal M.L., Yucel M., Nelson B., Yung A.R., Jackson G., McGorry P.D., Velakoulis D., Pantelis C. Hippocampal pathology in individuals at ultra-high risk for psychosis: a multi-modal magnetic resonance study. NeuroImage 2010, 52:62-68.
158. van Haren N.E., Cahn W., Hulshoff Pol H.E., Kahn R.S. The course of brain abnormalities in schizophrenia: can we slow the progression?. J. Psychopharmacol. 2012, 26:8-14.
159. van Haren N.E., Hulshoff Pol H.E., Schnack H.G., Cahn W., Brans R., Carati I., Rais M., Kahn R.S. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol. Psychiatry 2008, 63:106-113.
160. van Haren N.E., Schnack H.G., Cahn W., van den Heuvel M.P., Lepage C., Collins L., Evans A.C., Hulshoff Pol H.E., Kahn R.S. Changes in cortical thickness during the course of illness in schizophrenia. Arch. Gen. Psychiatry 2011, 68:871-880.
161. van Os J., Kapur S. Schizophrenia. Lancet 2009, 374:635-645.